Destruction of Tumor Cells by Trifunctional Bispecific Antibodies With Low to Medium Expression Levels of Tumor-Associated Target Antigens
First Claim
Patent Images
1. A method for the treatment or prophylaxis of tumor diseases comprising administering to a patient in need thereof a pharmaceutically effective amount of a trifunctional bispecific antibody having the following properties:
- (a) binding to a T cell;
(b) binding to at least one tumor associated antigen on a tumor cell, said antigen being selected from the group consisting of Her2/neu, CD20, EpCAM, G250, proteoglycans, GD2, GD3, MHC II, EGF-R and CEA;
(c) binding via their Fc-portion to Fcγ
-receptor type I or III positive cells, or a combination thereof;
wherein said tumor-associated antigen is expressed on said tumor cellin an amount of about 5,000-150,000 tumor-associated antigens/tumor cell for Her2/neu, orin an amount of about up to 500,000 tumor-associated antigens/tumor cell for Her2/neu in tumor cells tested FISH negative, orin an amount of about 1,000 to about 350,000, or of up to about 310,00 or up to about 300,00 tumor associated antigens/tumor cell for CD20, orin an amount of about 1,000 to about 350,000 preferably of up to about 300,000 tumor-associated antigens/tumor cell for EpCAM, G250, proteoglycans, GD2, GD3, MHC II, EGF-R and CEA.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention describes the use of trifunctional bispecific antibodies for the preparation of a pharmaceutical composition for the prophylaxis and treatment of tumor diseases. It has been found that said trifunctional bispecific antibodies are binding to tumor-associated antigens selected from Her2/neu, CD20, EpCAM, G250, proteoglycans, GD3, GD2, MHC II, EGF-R and CEA, wherein said tumor-associated antigens are expressed on said tumor cell with a low to medium expression level only.
103 Citations
16 Claims
-
1. A method for the treatment or prophylaxis of tumor diseases comprising administering to a patient in need thereof a pharmaceutically effective amount of a trifunctional bispecific antibody having the following properties:
-
(a) binding to a T cell; (b) binding to at least one tumor associated antigen on a tumor cell, said antigen being selected from the group consisting of Her2/neu, CD20, EpCAM, G250, proteoglycans, GD2, GD3, MHC II, EGF-R and CEA; (c) binding via their Fc-portion to Fcγ
-receptor type I or III positive cells, or a combination thereof;wherein said tumor-associated antigen is expressed on said tumor cell in an amount of about 5,000-150,000 tumor-associated antigens/tumor cell for Her2/neu, or in an amount of about up to 500,000 tumor-associated antigens/tumor cell for Her2/neu in tumor cells tested FISH negative, or in an amount of about 1,000 to about 350,000, or of up to about 310,00 or up to about 300,00 tumor associated antigens/tumor cell for CD20, or in an amount of about 1,000 to about 350,000 preferably of up to about 300,000 tumor-associated antigens/tumor cell for EpCAM, G250, proteoglycans, GD2, GD3, MHC II, EGF-R and CEA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeHorst Lindhofer
-
Original AssigneeHorst Lindhofer
-
InventorsLindhofer, Horst
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current424/174.100
-
CPC Class CodesA61K 2039/505 comprising antibodiesA61K 2039/55 characterised by the host/r...A61P 35/00 Antineoplastic agentsA61P 35/04 specific for metastasisC07K 16/2809 against the T-cell receptor...C07K 16/2887 against CD20C07K 16/3084 against tumour-associated g...C07K 16/32 against translation product...C07K 2317/24 containing regions, domains...C07K 2317/31 multispecificC07K 2317/73 Inducing cell death, e.g. a...
